TotalMarketCap

Halozyme Therapeutics

HALONasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$14.029 B

$123.61 -5.16%

Close of 6 Nov 2026

As of 6 Nov 2026, Halozyme Therapeutics (HALO) has a market capitalization of $14.0B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.40B

#1331 by revenue

Earnings

$316.9M

#806 by earnings

Shares outstanding

114,010,000

Latest filing cover page

P/E ratio

44.3

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #8ExelixisEXEL$16.8B
  2. #9Neurocrine BiosciencesNBIX$16.2B
  3. #10Halozyme TherapeuticsHALO$14.0B
  4. #11Bio-TechneTECH$11.4B
  5. #12Kymera TherapeuticsKYMR$10.8B

What if Halozyme Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$248,787.41

Per share 2,013× higher

Bitcoin $1.53T

$13,461.45

Per share 109× higher

Apple $5.02T

$44,192.70

Per share 358× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Halozyme Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.